Physician profile
Anthony P Rota
NPI 1770624686
$2,196.54
in general payments reported to CMS, 2019-2025
25 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $204 · 2021: $293 · 2022: $411 · 2023: $436 · 2024: $285 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $377.25 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $285.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $209.26 | 2019-2024 | Vaqta, Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $187.68 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $187.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $177.07 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $99.23 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.52 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $79.01 | 2022-2023 | Quviviq |
| Abbott Laboratories | $70.12 | 2022-2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $58.29 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $53.88 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.32 | 2019-2022 | |
| Amarin Pharma, INC. | $43.31 | 2020-2022 | |
| Abbvie INC. | $39.91 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.82 | 2024 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $29.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.46 | 2022 | |
| Coloplast Corp | $20.01 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.23 | 2021 | |
| Bavarian Nordic A/S | $14.09 | 2025 | Vivotif |
| Allergan, INC. | $13.75 | 2019 | |
| Astellas Pharma US INC | $13.30 | 2024 | Veozah |
| Amgen INC. | $13.24 | 2019 | |
| Kaleo, INC. | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Rota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.